Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Extrawell Pharmaceutical Holdings Gross Margin %?
Extrawell Pharmaceutical HoldingsHKSE:00858 -1.19% Gross Margin % is 44.64% as of Mar. 2026, which is 9% below its 10-year median of 48.87. The stock has 5 warning signs investors should review. Among 941 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 56.11% on this metric.
HKSE:00858's Gross Margin % is ranked worse than 56.11% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.28
vs HKSE:00858: 44.19
Extrawell Pharmaceutical Holdings had a gross margin of 44.64% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Extrawell Pharmaceutical Holdings had a gross margin of 44.64% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Extrawell Pharmaceutical Holdings Gross Margin % Related Terms
Extrawell Pharmaceutical Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a Gross Margin % of 44.64% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Extrawell Pharmaceutical Holdings and its competitors. This is near median its historical median of 48.87. Over the past decade, Extrawell Pharmaceutical Holdings' Gross Margin % has ranged from 39.46 to 55.59. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #528 out of 941 companies in the Drug Manufacturers industry, placing it in the top 56.1%.
Is Extrawell Pharmaceutical Holdings' Gross Margin % too high?
Extrawell Pharmaceutical Holdings' current Gross Margin % of 44.64% is near median its 10-year median of 48.87. Over the past 10 years, this metric has ranged from a low of 39.46 to a high of 55.59. The Drug Manufacturers industry median Gross Margin % is 48.28. Extrawell Pharmaceutical Holdings' value of 44.64% is 7.5% below this industry median. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #528 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Extrawell Pharmaceutical Holdings' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #528 out of 941 companies for Gross Margin %. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median Gross Margin % is 48.28. Extrawell Pharmaceutical Holdings' value of 44.64% is 7.5% below this benchmark. Historically, Extrawell Pharmaceutical Holdings' own Gross Margin % has ranged from 39.46 to 55.59 over the past decade. While the company's 10-year median is 48.87 vs. the industry median of 48.28, Extrawell Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.28, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extrawell Pharmaceutical Holdings's current Gross Margin % of 44.64% is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current Gross Margin % is 44.64%, which is near median its own 10-year median of 48.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 66% above its estimated fair value. The current Gross Margin % is 44.64%, which is near median its 10-year median of 48.87 and 7.5% below the Drug Manufacturers industry median of 48.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current Gross Margin % is 44.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
